The Venture Codex

Participated · Series D · May 2023

RedDress develops personalized and autologous wound management solutions derived from patients' own blood, marketed under its ActiGraft product suite. ActiGraft systems treat a wide variety of chronic and acute wounds, including diabetic and neuropathic ulcers, venous ulcers, pressure injuries, traumatic and post-surgical wounds, skin tears and more. The company received FDA clearance and a CE Mark in 2020; its systems are available in 40 countries across five continents and have helped over 6,000 patients. RedDress is led by CEO Alon Kushnir and operates a U.S. subsidiary, RedDress Inc., in Jacksonville, Florida. The company plans to use the new funding to support increased adoption of its product suite, establish global partnerships, and expand its proprietary blood-based technology. The recent Series D also brought the company's total known funding to $43M.

Participated · Equity · Jun 2022

LUSIX produces lab-grown diamonds (LGDs) and markets them under the Sun Grown Diamonds™ mark, emphasizing 100% solar-powered production and proprietary reactor technology. The company is vertically integrated, designing and manufacturing its own reactors and producing custom-shaped and custom-colored rough diamonds for leading luxury brands. LUSIX was founded within Landa Labs by Benny Landa and spun off in 2016; its co-founder and current CTO is Dr. Yossi Yayon. The company highlights externally audited sustainability and third-party certification for traceability and quality. LUSIX plans to expand production with a second 100% solar-powered, state-of-the-art facility in Israel that will begin production this summer to meet rising global demand. The recent financing will be used to fuel these growth initiatives and scale capacity.